Login / Signup

Topical resiquimod dosing regimens in patients with multiple actinic keratoses: a multicentre, partly placebo-controlled, double-blind clinical trial.

E StockflethG F L HofbauerU ReinholdG PoppU R HenggeR M SzeimiesH BrüningM AnlikerT HungerR DummerC UlrichR KenzelmannChristian SurberL E French
Published in: The British journal of dermatology (2018)
Resiquimod 0·03% gel is more effective than 0·01% gel. From the perspectives of safety and tolerability, the lower concentration and shorter duration are preferable. The clinical response in arms 2/3 was reached with fewer gel applications. The dosing regimens that used the biological end point (arms 4/5) proved equally efficacious as predefined treatment durations and may therefore be suitable for personalized AK treatment.
Keyphrases
  • double blind
  • placebo controlled
  • clinical trial
  • study protocol
  • open label
  • phase iii
  • phase ii
  • wound healing
  • randomized controlled trial
  • hyaluronic acid
  • radiation therapy
  • replacement therapy
  • smoking cessation